For postmenopausal women with hormone receptor–positive BC [1], long-term use of an aromatase inhibitor (AI) for 5 to 10 years after primary surgical treatment has been demonstrated to prevent disease relapse and improve disease-free survival [2-4]. Here, CYP19A1 is linked to breast cancer.